Biosynthetic recombinant human fibronectin and preparation method
Through screening and recombinant technology, the problem of stability and low expression in the expression process of recombinant human chemical fibronectin was solved, and the biosynthesis of high stability and excellent cell adhesion activity was achieved, and fibronectin was opened up in medical and cosmetic surgery wide application pathways in the field.
Patent Information
- Application Number
- PCT/CN2023/110757
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2023-08-02
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art encountered difficulties in the expression of recombinant human chemical fibronectin, low expression amount and poor fragment stability in the process of recombinant human chemical fibronectin, lack of fibronectin products suitable for medical devices, and its application prospects in the field of beauty and medical care Not fully explored.
By preparing different fragments from human fibronectin and expressing them in recombinant manner, polypeptide sequences that are easy to purify and high expression are screened out, and biosynthetic recombinant human chemical fibronectin is generated by genetic engineering methods, achieving high stability and excellence cell adhesion activity.
Successfully biosynthesis and recombinant human chemical fibronectin have good cell adhesion effect and high stability. It is suitable for cosmetic and medical fields, especially in wrinkle removal, spot lightening and whitening, tumors, anti-infection and skin wound repair. Application prospects.
Smart Images

Figure PCTCN2023110757-FTAPPB-I100001 
Figure PCTCN2023110757-FTAPPB-I100002 
Figure PCTCN2023110757-FTAPPB-I100003
Abstract
Description
Biosynthetic recombinant humanized fibronectin and preparation method
[0001] This application claims priority to U.S. Patent Application No. 202310523607.7, filed May 10, 2023, entitled “Biosynthetic Recombinant Humanized Fibronectin and Method for Its Preparation,” which is incorporated herein by reference. Technical Field
[0002] The present invention relates to the field of synthetic biology, and in particular to a method for biosynthesizing recombinant humanized fibronectin. Background Art
[0003] Aging has become a hot topic of global concern. According to information released by the World Health Organization in 2021, it is projected that by 2050, the proportion of the global population aged 65 and over will reach 15.6%, more than double the proportion of children under 5 years old (7.2%). Data from my country's seventh census shows that the population aged 65 and over accounts for 13.50%. Currently, mainstream theories of aging include oxidative stress, immunosenescence, and DNA damage, which reveal the aging process from different perspectives. Under normal circumstances, the body's metabolism produces reactive oxygen species to maintain redox balance. Reactive oxygen species also participate in cell signaling regulation, including activation of the p38MAPK signaling pathway, which induces cell apoptosis and leads to cell growth arrest. Simultaneously, the aging of the immune system parallels the aging of the body. Studies have shown that the number and function of immune cells in the elderly are impaired to varying degrees. The immune system not only protects the body from pathogens but also promptly eliminates senescent cells, maintaining a stable internal environment.
[0004] Cells, through the interaction of cell surface integrins (also known as integrins) with the extracellular matrix, generate a complex series of signaling events that regulate cell growth, differentiation, adhesion, and motility. Research has shown that fibronectin (FN) participates in cell migration, adhesion, proliferation, hemostasis, tissue repair, and embryonic development by binding to integrins, particularly cell-anchoring junction proteins. It acts as a growth factor, inducing epidermal cells to form granulation tissue and promoting subepidermal basement membrane remodeling and normal keratinization. Studies in mice have shown that reduced FN levels in aged skeletal muscle stem cells (MuSCs) lead to deficiencies in number (significant only in young mice), function, and muscle maintenance. Restoring FN in aged mice restores the phenotype, level, muscle maintenance, and function of skeletal muscle stem cells to those of young mice. FN has been found to be the preferred adhesion substrate for MuSCs, regulating the p38 MAPK senescence pathway through integrins and focal adhesion kinase (FAK). Restoring FN attachment in the aged niche reactivates FAK signaling in MuSCs, thereby restoring the regenerative capacity of aged skeletal muscle. FN also exhibits a conditioning effect, promoting the uptake of tissue debris by phagocytes and providing a favorable internal and external environment for the metabolism of newly formed cells.
[0005] Fibronectin (FN) is a high-molecular-weight glycoprotein with a molecular weight of approximately 450 daltons that is widely present in blood, body fluids, and various tissues. It is a dimer composed of two 220,000 dalton subunits linked by disulfide bonds. The overall molecule is V-shaped, consisting of two similar A and B chains. Analysis of amino acid, gene, and genomic DNA sequences indicates that FN is a multidomain glycoprotein composed of a series of repeating modules: 12 FN-type repeats (FN I), two FN-type repeats (FN II), 15 constitutively expressed and two alternatively spliced FN-type III repeats (FN III), and a nonhomologous variable (V) or type III connecting segment (IIICS) region. This multimodular structure and intermodular regions provide flexibility to the FN molecule and contribute to its functional regulation.
[0006] Since the beginning of the 21st century, molecular biology has entered an era of rapid development, leading to the rise of human tissue engineering and promoting breakthroughs in microscopic research on fibronectin (FN). Research in emerging fields such as oncology and biomaterials has also mushroomed. In recent years, research on the clinical application value and scope of fibronectin (FN) has increased. Through the efforts of numerous scientific researchers, physicians, and scholars engaged in translational medicine and clinical application research, breakthroughs have been made in the research and application of oncology, anti-infection, and biomaterials. In skin wound repair and healing, fibronectin can shorten wound healing time and reduce scarring, and is widely used in regenerative medicine. In skin care, fibronectin (FN) has multiple uses, specifically: wrinkle reduction, spot lightening, and whitening effects.
[0007] Due to its unique value, some domestic biotech companies have launched beauty products containing fibronectin (FN). Consequently, fibronectin is widely used in the fields of beauty and medicine. In recent years, with the development of functional skincare products, domestic research into the medical application of fibronectin has revealed its unique efficacy in medical aesthetics. Dermatologists have been actively researching its application in functional skincare, but currently, no medical device products exist.
[0008] There is an urgent need for a fibronectin that can be used as a medical device, and it has broad application prospects in cosmetic aspects such as wrinkle removal, freckle lightening and whitening, as well as in medical fields such as tumor treatment, anti-infection, and skin wound repair.
[0009] Summary of the Invention
[0010] In response to current research and application, the inventors prepared different human fibronectin fragments from human fibronectin and attempted to express them recombinantly. The inventors discovered that recombinant expression of different human fibronectin fragments can encounter technical issues such as inability to undergo enzymatic cleavage, low expression levels, and poor fragment stability. After a series of screening, the inventors obtained a human fibronectin fragment that is easy to recombinantly express, has high expression levels, and is highly stable. Surprisingly, the inventors also discovered that this human fibronectin fragment exhibits excellent cell adhesion activity.
[0011] The present inventors provide a polypeptide: SSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTP.
[0012] The polypeptide is derived from human fibronectin and is a natural polypeptide that does not induce an immune response in the human body. The polypeptide can be a biosynthetic recombinant humanized fibronectin. The inventors generated the polypeptide described herein through genetic engineering methods. Specifically, the inventors achieved the production of the polypeptide through steps such as functional region screening, bacterial strain construction; large-scale biological fermentation culture and protein induced expression; purification of humanized fibronectin and optional enzymatic cleavage. The inventors found that compared with other peptide segments of human fibronectin, the polypeptide of the present invention is easy to purify, stable, and has the effect of promoting cell adhesion.
[0013] In one aspect, provided herein is a polypeptide comprising the following amino acid sequence:
[0014] (1) Amino acid sequence shown in SEQ ID NO: 1: SSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTP;
[0015] (2) an amino acid sequence having 80%, 85%, 90%, 95%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1; or
[0016] (3) An amino acid sequence in which one or more amino acids are substituted, inserted, deleted or added in the amino acid sequence shown in SEQ ID NO: 1.
[0017] In one embodiment, the polypeptide is derived from human fibronectin.
[0018] In one embodiment, the amino acid substitutions are conservative amino acid substitutions.
[0019] In one embodiment, the amino acid additions are referenced to those of human fibronectin, such that the polypeptide is a native fragment of human fibronectin.
[0020] In one embodiment, the polypeptide has the function of fibronectin.
[0021] In one aspect, the present invention provides a fusion protein comprising one or more polypeptides described herein as repeating units. The repeating units can be connected directly or indirectly through a linker. Optionally, the fusion protein further comprises another proteinaceous portion, such as a polypeptide having a beauty / cosmetic function.
[0022] In one aspect, provided herein are nucleic acids encoding a polypeptide or fusion protein as described herein. In one embodiment, the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO: 2.
[0023] In one aspect, provided herein are vectors comprising a nucleic acid as described herein. In one embodiment, the vector comprises nucleotides encoding a purification tag, nucleotides encoding a leader, and / or regulatory elements.
[0024] In one embodiment, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag. In one embodiment, the regulatory element is selected from a promoter, a terminator and / or an enhancer.
[0025] In one aspect, provided herein is a host cell comprising a nucleic acid as described herein or a vector as described herein. In one embodiment, the host cell is a eukaryotic cell or a prokaryotic cell. In one embodiment, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an Escherichia coli cell, such as Escherichia coli BL21.
[0026] In one aspect, provided herein are methods for producing a polypeptide as described herein, comprising:
[0027] (1) culturing the host cell described herein under appropriate culture conditions;
[0028] (2) harvesting the host cells and / or culture medium containing the polypeptide; and
[0029] (3) Purifying the fusion protein, for example, including (1) purifying the polypeptide on a Ni affinity chromatography column; (2) adding TEV enzyme for cleavage; and / or (3) purifying the polypeptide on an ion exchange column.
[0030] In one aspect, provided herein are compositions comprising a polypeptide described herein, a fusion protein described herein, a nucleic acid described herein, a vector described herein, and / or a host cell described herein.
[0031] In one embodiment, the composition is a pharmaceutical composition, a food composition, or a cosmetic composition.
[0032] In one embodiment, the cosmetic composition is a skin anti-wrinkle, spot lightening and / or skin whitening cosmetic composition.
[0033] In one embodiment, the composition is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.
[0034] In one embodiment, the composition comprises a pharmaceutically, cosmetically and / or food acceptable carrier.
[0035] In one embodiment, the composition is a solid, liquid or gel composition.
[0036] In one embodiment, the composition is a kit.
[0037] In one embodiment, the composition is a liquid formulation comprising a polypeptide as described herein or a fusion protein as described herein and a pharmaceutically, cosmetically and / or food acceptable carrier.
[0038] In one embodiment, the liquid formulation comprises sodium chloride, Tris and imidazole. In one embodiment, the sodium chloride concentration is 100-300mM, for example, 120, 150, 170, 200, 220, 250 or 270mM. In one embodiment, the Tris concentration is 10-50mM, for example, 20, 30 or 40nM. In one embodiment, the imidazole concentration is 100-300nM, for example, 120, 150, 170, 200, 220, 250 or 270mM. In one embodiment, the pH of the liquid formulation is 6-10, for example, 6.5, 7.5, 8, 8.5, 9, or 9.5. In one embodiment, the liquid formulation comprises 200mM sodium chloride, 25mM Tris, 250mM imidazole, pH 8.0
[0039] In one aspect, provided herein are cosmetic or beauty methods comprising applying to the skin a polypeptide, fusion protein, and / or composition described herein, and optionally applying to the skin other cosmetic and / or beauty products.
[0040] In one embodiment, the cosmetic or beauty method is a skin anti-wrinkle, lightening and / or whitening method.
[0041] In one embodiment, administration is topical or dermal administration.
[0042] In one aspect, provided herein is the use of a polypeptide, fusion protein, nucleic acid, vector and / or host cell described herein in a pharmaceutical, cosmetic or beauty product.
[0043] In one embodiment, the product is a topical product.
[0044] In one embodiment, the cosmetic or beauty product is a skin anti-wrinkle, oil control, repair and / or soothing product.
[0045] In one embodiment, the product is selected from biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, and 3D printed artificial organ biomaterials.
[0046] In one aspect, the present invention provides the use of the polypeptides, fusion proteins, nucleic acids, vectors and / or host cells described herein in preparing a kit for treating or assisting in the treatment of tumors, anti-infection and / or skin wound repair.
[0047] Advantages of the present invention:
[0048] 1. The present invention provides the core functional region and amino acid sequence of recombinant humanized fibronectin.
[0049] 2. The present invention successfully biosynthesized recombinant humanized fibronectin for the first time, which is easy to purify and stable during storage.
[0050] 3. The polypeptide prepared by the present invention (eg, recombinant humanized fibronectin) has good cell adhesion effect, is derived from natural human protein, and will not produce an immune response when applied to the human body.
[0051] 4. The present invention adopts a biosynthetic method to achieve large-scale preparation of recombinant humanized fibronectin.
[0052] 5. The recombinant humanized fibronectin prepared by the present invention is expected to be widely used in cosmetic fields such as wrinkle removal, spot lightening and whitening, as well as in medical fields such as tumors, anti-infection, and skin wound repair.
[0053] 6. The FST5 protein of the present invention was expressed in E. coli at a high protein expression level and exhibited high stability when stored at room temperature, indicating that the FST5 protein possessed high storage stability. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 shows the electrophoresis detection of TEV enzyme digestion of the purified FST1, FST2, FST3, and FST4 proteins. After expression, the FST1, FST2, FST3, and FST4 polypeptides have abnormal protein structures and cannot be digested by enzymes.
[0055] Figure 2 shows the electrophoresis results of FST8 expression. The target protein was precipitated after homogenization.
[0056] FIG3 shows the results of electrophoresis detection of FST5.
[0057] FIG4 shows the electrophoresis detection results of FST6.
[0058] FIG5 shows the results of electrophoresis detection of FST7.
[0059] Figure 6 shows the stability results of FST5 and FST7 after being placed at room temperature for 2 hours.
[0060] FIG7 shows the results of a cell adhesion experiment of the recombinant humanized fibronectin FST5 of the present invention. DETAILED DESCRIPTION
[0061] To make the objectives, technical solutions, and advantages of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.
[0062] As used herein, fibronectin (FN) is a high-molecular-weight glycoprotein with a molecular weight of approximately 450 daltons that is widely present in blood, body fluids, and various tissues. It is a dimer composed of two subunits with a molecular mass of 220,000 daltons connected by disulfide bonds. The entire molecule is composed of two similar A chains and B chains, forming a V shape. According to analysis of amino acid, gene, and genomic DNA sequences, fibronectin (FN) is a multidomain glycoprotein composed of a series of multiple repeating module structures, including 12 FNI-type repeats (FN I), 2 FNII-type repeats (FN II), 15 constitutively expressed and 2 alternatively spliced FN III-type (FN III) repeats, and a non-homologous variable (V) or type III connecting segment (IIICS) region. The multi-module structure and inter-module region give the fibronectin (FN) molecule flexibility and participate in regulating its function.
[0063] As used herein, a peptide or polypeptide refers to a plurality of amino acid residues linked by peptide bonds. The polypeptides described herein may be naturally occurring polypeptides derived from human fibronectin, or fragments of human fibronectin. The polypeptides or fragments described herein retain the various functions of human fibronectin, such as adhesion, wrinkle removal, spot lightening, and whitening.
[0064] As used herein, "nucleic acid" refers to a plurality of nucleotides linked by internucleotides. Internucleotide linkages can be, for example, phosphodiester bonds. The nucleic acids herein can comprise polynucleotides encoding the polypeptides of the present invention. To facilitate subsequent processing of the polypeptides, the nucleic acids of the present invention can also comprise nucleotides encoding purification tags, such as His tags, GST tags, MBP tags, SUMO tags, or NusA tags, and, when necessary, nucleotide sequences encoding leader sequences. The nucleic acids described herein can be nucleic acids encoding the polypeptides described herein. The nucleic acids can be codon-optimized for expression hosts. For example, in the examples herein, the encoding nucleic acids are codon-optimized for Escherichia coli. Codon-optimized methods are known to those skilled in the art.
[0065] As used herein, the term "vector" is a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, the vector is referred to as an expression vector. A vector can be introduced into a host cell by transformation, transduction, or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages such as lambda phage or M13 phage, and animal viruses. A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, a vector may also contain a replication initiation site. A vector can contain a nucleic acid of the present invention to facilitate introduction into cells for expression. A vector can contain expression control elements, such as a promoter, terminator, and / or enhancer, operably linked to the nucleic acid.
[0066] As used herein, the term "host cell" is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. These techniques include transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration. The host cell can be a eukaryotic cell or a prokaryotic cell. For example, a eukaryotic cell is a yeast cell, an animal cell, and / or an insect cell. The prokaryotic cell can be an Escherichia coli cell.
[0067] As used herein, the degree of association between two amino acid sequences or between two nucleotide sequences is described by parameter " sequence identity ".For purposes of the present invention, use as in the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. [genetics trend] 16:276-277) (preferred 5.0.0 version or updated version) Niederman-Wunsch algorithm (Needleman and Wunsch, 1970, J.Mol.Biol. [J.Molecular Biology] 48:443-453) determine the sequence identity between two amino acid sequences.The parameter used is gap opening penalty 10, gap extension penalty 0.5 and EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.The output (using non-simplified option to obtain) of Nieder, who is labeled as " longest identity ", is used as identity percentage and is calculated as follows:
[0068] (number of identical residues × 100) / (length of alignment - total number of gaps in the alignment)
[0069] For purposes of the present invention, the sequence identity between two deoxynucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented by the Needleman program of the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferred 5.0.0 version or later). The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needleman, labeled "longest identity," (obtained using the non-simplified option), which is labeled "longest identity," is used as percent identity and is calculated as follows:
[0070] (number of identical deoxyribonucleotides x 100) / (length of alignment - total number of gaps in the alignment)
[0071] Conservative substitutions can be defined by substitutions within the amino acid classes reflected in the table below:
[0072] Table 1: Amino acid residue categories for conservative substitutions
[0073] peptides
[0074] Herein, the polypeptide of the present invention may have the amino acid sequence of SSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTP, but may also contain certain mutations. For example, the amino acid sequence may contain substitutions, deletions, additions, or insertions of amino acid residues. In other words, variants can be used in the present invention as long as the variant retains the activity of fibronectin. Specifically, the variant may have a certain percentage identity with the specified sequence SEQ ID NO:1, for example, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity. The polypeptide of the present invention may have one or more of the following functions: anti-wrinkle, spot-lightening, and / or skin-whitening functions.
[0075] The polypeptides of the present invention can be prepared by any suitable means, for example, by synthesis. Preferably, the polypeptides of the present invention can be prepared by recombinant means or genetic engineering.
[0076] The polypeptides of the present invention can be prepared as fusion proteins. Fusion proteins can include one or more polypeptides described herein as repeating units. The repeating units can be linked directly or indirectly via a linker. For example, a fusion protein can include 2-10, such as 3, 4, 5, 6, 7, 8, or 9 linked polypeptides described herein.
[0077] Composition
[0078] The polypeptide or fusion protein of the present invention can be prepared as a composition. The composition can include the polypeptide, fusion protein, nucleic acid, vector and / or host cell described herein. The composition can also include a pharmaceutically, cosmetically and / or food-acceptable carrier or solvent. The composition can be a pharmaceutical composition, a food composition or a cosmetic composition, used for pharmaceutical, food and / or cosmetic purposes. For example, the composition is one or more of a biological dressing, a human biomimetic material, a plastic surgery material, an organoid culture material, a cardiovascular stent material, a coating material, a tissue injection filling material, an ophthalmic material, a gynecological biomaterial, a nerve repair and regeneration material, a liver tissue material and a vascular repair and regeneration material, a 3D printed artificial organ biomaterial, a cosmetic raw material, a pharmaceutical excipient and a food additive.
[0079] The cosmetic composition can be a skin anti-wrinkle, spot lightening and / or whitening cosmetic composition. The part where the cosmetic composition is applied is not particularly limited, and can be the face, hands, legs, trunk, etc.
[0080] The form of the composition is not particularly limited as long as the intended function can be achieved. For example, the composition is a solid, liquid or gel composition.
[0081] method
[0082] Also provided herein are cosmetic or beauty methods comprising applying to the skin a polypeptide, fusion protein, and / or composition as described herein. Application to the skin may be topical, for example, to a region of the skin requiring skin anti-wrinkle, blemish-lightening, and / or whitening effects. The methods may also include applying other cosmetic and / or beauty products to the skin. The types of other cosmetic and / or beauty products are not particularly limited and may include other cosmetics with skin anti-wrinkle, blemish-lightening, and / or whitening effects, such as collagen peptides.
[0083] use
[0084] Also provided herein are uses of polypeptides, fusion proteins, nucleic acids, vectors and / or host cells in medicines, cosmetics or beauty products. These products can be external use products, such as external use cosmetics or beauty products. These cosmetics or beauty products can be skin anti-wrinkle, oil control, repair and / or soothing products. For example, the product can be selected from biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials. Also provided herein are uses of the polypeptides, nucleic acids, vectors and / or host cells described herein in the preparation of kits for treating or assisting in the treatment of tumors, anti-infection and / or skin wound repair.
[0085] Exemplary embodiments
[0086] 1. In view of the current research status, the present invention provides a method for biosynthesizing recombinant humanized fibronectin, which specifically includes: (1) screening of functional regions and construction of bacterial strains; (2) large-scale biological fermentation culture and induced expression of protein; (3) purification of humanized fibronectin and optional enzymatic cleavage.
[0087] 2. According to item 1, functional region screening and strain construction can be carried out as follows: (1) large-scale functional region screening to obtain the functional region of the target gene; (2) inserting the obtained functional region of the target gene into the pET-32a expression vector to obtain a recombinant expression plasmid; (3) transferring the recombinant expression plasmid into the Escherichia coli competent cell BL21 (DE3) and screening to obtain positive Escherichia coli genetically engineered bacteria.
[0088] 3. According to item 1, large-scale biofermentation can be carried out as follows: the positive genetically engineered Escherichia coli obtained by screening is added to a shake flask containing an antibiotic stock solution and cultured in a constant temperature shaker at 220 rpm and 37°C for 7 hours.
[0089] 4. According to item 1, the protein can be induced to express as follows: (1) cool the shake flask after culture to 16°C; (2) add IPTG mother solution to induce expression; (3) place the induced bacterial solution in a centrifuge bottle, centrifuge at 8000 rpm and 4°C for 10 minutes, and then collect the bacteria.
[0090] 5. According to item 1, the purification and optional enzymatic cleavage of recombinant humanized fibronectin can be carried out as follows: (1) crude purification of recombinant humanized fibronectin on a Ni affinity chromatography column; (2) addition of TEV enzyme for enzymatic cleavage in a certain proportion; (3) fine purification of recombinant humanized fibronectin on an ion exchange column.
[0091] 6. According to item 2, the functional regions screened out are as follows: FST5 amino acid sequence: SSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTP.
[0092] 7. The amino acid sequence of the recombinant humanized fibronectin prepared by the present invention is derived from the functional region of natural human fibronectin, including this functional region and similar functional regions, and proteins with mutated and modified amino acid sequences.
[0093] 8. The recombinant humanized fibronectin prepared by the present invention is expected to be widely used in cosmetic fields such as wrinkle removal, spot lightening and whitening, as well as in medical fields such as tumors, anti-infection, and skin wound repair.
[0094] Example
[0095] The present invention is further illustrated by the following examples, but any example or combination thereof should not be construed as limiting the scope or implementation of the present invention. The scope of the present invention is defined by the appended claims. In conjunction with this specification and common knowledge in the art, a person of ordinary skill in the art will clearly understand the scope defined by the claims. Without departing from the spirit and scope of the present invention, those skilled in the art may make any modifications or changes to the technical solution of the present invention, and such modifications and changes are also included in the scope of the present invention.
[0096] Example 1: Construction, expression and screening of fibronectin fragments
[0097] 1. Perform large-scale functional region screening to obtain the following different target gene functional regions of recombinant humanized fibronectin.
[0098] FST1 amino acid sequence:
[0099] FST2 amino acid sequence:
[0100] FST3 amino acid sequence:
[0101] FST4 amino acid sequence:
[0102] FST5 amino acid sequence:
[0103] FST6 amino acid sequence:
[0104] FST7 amino acid sequence:
[0105] FST8 amino acid sequence:
[0106] 2. Nucleotide sequence
[0107] FST1 nucleotide sequence:
[0108] FST2 nucleotide sequence:
[0109] FST3 nucleotide sequence:
[0110] FST4 nucleotide sequence:
[0111] FST5 nucleotide sequence (SEQ ID NO: 2):
[0112] FST6 nucleotide sequence:
[0113] FST7 nucleotide sequence:
[0114] FST8 nucleotide sequence:
[0115] Each of the above encoding nucleotide sequences was inserted into the pET-28a-Trx-His expression vector to obtain a recombinant expression plasmid.
[0116] 3. Transform the successfully constructed expression plasmid into E. coli competent cells BL21 (DE3). The specific process is as follows: (1) Take out the E. coli competent cells BL21 (DE3) from the ultra-low temperature refrigerator and place them on ice. When they are half melted, take 2 μl of the plasmid to be transformed and add it to the E. coli competent cells BL21 (DE3), and mix it slightly 2-3 times. (2) Place the mixture on ice for 30 minutes, then heat shock it in a 42°C water bath for 45-90 seconds, take it out and place it on ice for 2 minutes. (3) Transfer it to a biosafety cabinet and add 700 μl of liquid LB culture medium, then incubate it at 37°C and 220 rpm for 60 minutes. (4) Take 200 μl of the bacterial solution and evenly spread it on an LB plate containing ampicillin sodium. (5) Incubate the plate in a 37°C incubator for 15-17 hours until colonies of uniform size grow.
[0117] 4. Pick 5-6 single colonies from the transformed LB plate and place them in a shake flask containing LB medium containing antibiotic stock solution. Incubate in a shaker at 220 rpm and 37°C for 7 hours. Cool the shake flask to 16°C and add IPTG to induce expression for a period of time. Then, divide the culture into centrifuge bottles and centrifuge at 8000 rpm and 4°C for 10 minutes. Collect the cells and record the cell weight. Take a sample (labeled "cell solution") for electrophoresis.
[0118] 5. Resuspend the collected cells in a balanced working solution (200mM NaCl, 25mM Tris, 20mM imidazole, pH 8.0). Cool the solution to ≤15°C and homogenize. Homogenize twice with high pressure (take samples from each homogenization and label them as "homogeneous one" and "homogeneous two"). After completion, collect the solution. Aliquot the homogenized solution into centrifuge bottles and centrifuge at 17,000 rpm and 4°C for 30 minutes. Collect the supernatant and perform electrophoresis on the supernatant and precipitate.
[0119] 6. Recombinant human fibronectin was purified and enzymatically digested. The specific process was as follows: (1) Crude purification: a. Wash the column (Ni6FF, Cytiva) with water for 5 CV. b. Equilibrate the column with equilibration solution (200 mM sodium chloride, 25 mM Tris, 20 mM imidazole, pH 8.0) for 5 CV. c. Loading: Add the supernatant after centrifugation to the column until the liquid has flowed out, and take the flow-through for electrophoresis (marked as flow-through). d. Cleaning impurities: Add 25 mL of washing solution (200 mM sodium chloride, 25 mM Tris, 20 mM imidazole) until the liquid has flowed out, and take the wash flow-through for electrophoresis (marked as wash impurities). e. Collect the target protein: add 20 mL of eluent (200 mM sodium chloride, 25 mM Tris, 250 mM imidazole, pH 8.0) and collect the flow-through (marked as: elution), detect the protein concentration and calculate the protein amount, and perform electrophoresis detection. f. Wash the column with 1 M imidazole working solution (marked as 1 M wash). g. Wash the column with purified water. (2) Enzyme digestion: add TEV enzyme at a ratio of 50:1 between the total amount of protein and the total amount of TEV enzyme, digest at 16°C for 4 hours, and take a sample for electrophoresis detection. Place the protein solution after enzyme digestion in a dialysis bag, dialyze at 4°C for 2 hours, and then transfer to new dialysis solution for dialyzation at 4°C overnight. (3) Purification: a. Equilibrate the column: Use solution A (20 mM Tris, 20 mM sodium chloride, pH 8.0) to equilibrate the column at a flow rate of 10 ml / min. b. Load the sample: load the sample at a flow rate of 5 ml / min, collect the flow-through, and perform electrophoresis detection. c. Gradient elution: Set the concentrations to 0-15% Solution B (20 mM Tris, 1 M NaCl, pH 8.0) for 2 min and hold for 3 CVs, 15-30% Solution B for 2 min and hold for 3 CVs, 30-50% Solution B for 2 min and hold for 3 CVs, and 50-100% Solution B for 2 min and hold for 3 CVs. Collect peaks and perform electrophoresis (labeled as purified protein). d. Wash the column. Store the protein at 4°C.
[0120] 7. Concentration detection
[0121] Accurately measure an appropriate amount of sample, dilute 10-50 times with eluent, and stir thoroughly with a glass rod. Measure the absorbance at 280 nm using a UV-visible spectrophotometer. Calculate the protein concentration using the formula C (mg / ml) = A280 × Absorption Coefficient × Dilution Factor (Note: The absorbance value must be between 0.1 and 1).
[0122] The concentration test results are as follows:
[0123] The protein expression levels were FST5>FST7>FST2>FST1>FST6>FST4>FST3>FST8.
[0124] 8. Electrophoresis detection
[0125] The specific process is as follows: take 40 μl of sample liquid, add 10 μl of 5× protein loading buffer (250 mM Tris-HCl (pH: 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), place it in boiling water at 100°C for 10 minutes, then add 10 μl to each well of SDS-PAGE protein gel, run at 80 V for 2 hours, and then use Coomassie Brilliant Blue staining solution (0.1% Coomassie Brilliant Blue R-250, 25% isopropanol, 10% glacial acetic acid) for protein staining for 20 minutes, and then use protein decolorization solution (10% acetic acid, 5% ethanol) for decolorization.
[0126] The electrophoresis test results showed:
[0127] The purified proteins of FST1, FST2, FST3, and FST4 could not be cleaved by enzymes (see Figure 1). These four proteins expressed abnormally and performed poorly. The target protein expressed by FST8 was expressed as inclusion bodies in the precipitate after homogenization and was not suitable for subsequent purification (see Figure 2). The target protein was expressed by FST6 (see Figure 4), but the protein expression level was low. The protein purification effects of FST5 (see Figure 3) and FST7 (see Figure 5) were better.
[0128] 9. Protein Stability Observation
[0129] Purified FST5 and FST7 protein solutions (5 mg / ml protein, 200 mM NaCl, 25 mM Tris, 250 mM imidazole, pH 8.0) were incubated at room temperature for 2 hours. The protein properties were then observed, as shown in Figure 6. FST5 was clear and translucent, while FST7 was whitish, turbid, and less stable. Therefore, the FST5 plasmid performed better. The purified FST5 protein was then tested.
[0130] Example 2: Mass spectrometry detection of recombinant human fibronectin FST5
[0131] Experimental methods
[0132] After DTT reduction and iodoacetamide alkylation, the protein sample was digested with trypsin overnight. The resulting peptides were desalted using a C18 ZipTip and then spotted with the matrix α-cyano-4-hydroxycinnamic acid (CHCA). Finally, analysis was performed using a matrix-assisted laser desorption / ionization-time-of-flight mass spectrometer (MALDI-TOF / TOF Ulraflextreme™, Brucker, Germany). (For peptide fingerprinting techniques, see Protein J. 2016;35:212-7.)
[0133] Data retrieval was performed using the MS / MS Ion Search page on the local Masco website. Protein identification was based on the primary mass spectra of peptides generated after enzymatic digestion. Detection parameters: Trypsin digestion with two missed cleavage sites. Alkylation of cysteine was set as a fixed modification. Oxidation of methionine was set as a variable modification. The NCBprot database was used for identification.
[0134] Table 1: Mass spectrometry detected molecular weight of recombinant human fibronectin FST5 and corresponding peptides
[0135] The coverage of the detected polypeptide fragments compared with the theoretical sequence was 94%, and the detection results were very reliable.
[0136] Example 3: Detection of biological activity of recombinant human fibronectin FST5
[0137] The method for detecting protein adhesion activity can be found in the literature Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura, Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). The specific implementation method is as follows:
[0138] (1) The concentration of the protein sample to be tested was detected by ultraviolet absorption method, including bovine type I collagen (China Food and Drug Inspection Institute, No.: 380002) and the recombinant humanized fibronectin FST5 provided by the present invention.
[0139] Specifically, the sample's UV absorbance at 215 nm and 225 nm is measured, and the protein concentration is calculated using the empirical formula C (μg / mL) = 144 × (A215 - A225). Note that the assay must be performed when A215 < 1.5. This method, which measures the characteristic absorption of peptide bonds under far-UV light, is unaffected by chromophore content, exhibits minimal interfering substances, and is simple to perform. It is suitable for detecting human collagen and its analogs, which do not develop color with Coomassie Brilliant Blue. (Reference: Walker JM. The Protein Protocols Handbook, second edition. Humana Press. 43-45.) After measuring the protein concentration, adjust the concentration of all tested proteins to 0.5 mg / mL with PBS.
[0140] (2) 100 μL of various protein solutions and a blank PBS solution control (see NC group in Figure 7) were added to a 96-well plate and allowed to stand at room temperature for 60 min.
[0141] (3) Add 10 5 3T3 cells in good culture condition were incubated at 37°C for 60 min.
[0142] (4) Wash each well 4 times with PBS.
[0143] (5) Detect the absorbance at OD492nm using the LDH detection kit (Roche, 04744926001). Calculate the cell adhesion rate based on the blank control value. The calculation formula is as follows: The cell adhesion rate reflects the adhesion activity of each protein. The higher the activity of the protein, the better the external environment it can provide to the cells in a short time, helping them to adhere to the wall.
[0144] The results are shown in Figure 7. The comparison demonstrates that the recombinant humanized fibronectin FST5 of the present invention exhibits superior bioadhesive activity compared to bovine type I collagen (PC group, 0.5 mg / ml). Figure 7 depicts the relative cell adhesion activity of FST5 relative to bovine type I collagen, demonstrating that FST5 exhibits significantly higher (more than two-fold) cell adhesion activity compared to bovine type I collagen. The high cell adhesion activity of FST5 was unexpected.
[0145] Although the present invention has been described with reference to illustrative embodiments, it will be understood by those skilled in the art that various other changes, omissions, and / or additions may be made and that substantial equivalents may be substituted for elements of the described embodiments without departing from the spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the present invention without departing from the scope of the invention. Therefore, it is not intended that the present invention be limited to the specific embodiments disclosed for carrying out the invention, but rather that the invention will encompass all embodiments falling within the scope of the appended claims.
Claims
1. A polypeptide comprising the following amino acid sequence: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) an amino acid sequence having 80%, 85%, 90%, 95%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1; or (3) an amino acid sequence in which one or more amino acids are substituted, inserted, deleted or added in the amino acid sequence shown in SEQ ID NO: 1; Preferably, the polypeptide is derived from human fibronectin; Preferably, wherein the amino acid substitution is a conservative amino acid substitution; Preferably, the amino acid addition is based on the amino acid addition of human fibronectin, so that the polypeptide is a fragment of human fibronectin; Preferably, the polypeptide has the function of fibronectin.
2. A fusion protein comprising one or more polypeptides according to claim 1, optionally further comprising another proteinaceous part, such as a polypeptide having a beauty / cosmetic function.
3. A nucleic acid encoding the polypeptide according to claim 1, preferably comprising the nucleotide sequence shown in SEQ ID NO: 2, or encoding the fusion protein according to claim 2.
4. A vector comprising the nucleic acid according to claim 2, optionally comprising nucleotides encoding a purification tag, nucleotides encoding a leader and / or a regulatory element; Preferably, the purification tag is selected from a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag; preferably, the regulatory element is selected from a promoter, a terminator and / or an enhancer.
5. A host cell comprising a nucleic acid according to claim 3 or a vector according to claim 4; wherein preferably, the host cell is a eukaryotic cell or a prokaryotic cell; wherein preferably, the eukaryotic cell is a yeast cell, an animal cell and / or an insect cell, and / or the prokaryotic cell is an Escherichia coli cell, such as Escherichia coli BL21.
6. Producing the polypeptide according to claim 1, comprising: (1) culturing the host cell according to claim 5 under suitable culture conditions; (2) harvesting host cells and / or culture medium containing the polypeptide; and (3) Purifying the fusion protein, for example, including (1) purifying the polypeptide on a Ni affinity chromatography column; (2) adding TEV enzyme for cleavage; and / or (3) purifying the polypeptide on an ion exchange column.
7. A composition comprising the polypeptide according to claim 1, the fusion protein according to claim 2, the nucleic acid according to claim 3, the vector according to claim 4 and / or the host cell according to claim 5; Preferably, the composition is a pharmaceutical composition, a food composition or a cosmetic composition, Preferably, the cosmetic composition is a skin anti-wrinkle, spot lightening and / or skin whitening cosmetic composition; Preferably, the composition is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives; Preferably, the composition comprises a pharmaceutically, cosmetically and / or food acceptable carrier; Preferably, the composition is a solid, liquid or gel composition; Preferably, the composition is a kit; Preferably, the composition is a liquid formulation comprising the polypeptide according to claim 1 and / or the fusion protein according to claim 2 and a pharmaceutically, cosmetically and / or food acceptable carrier; Preferably, the liquid formulation comprises sodium chloride, Tris and imidazole; Preferably, the sodium chloride concentration is 100-300 mM; Preferably, the Tris concentration is 10-50 mM; Preferably, the imidazole concentration is 100-300 nM; Preferably, the pH of the liquid formulation is 6-10.
8. A cosmetic or beauty method, comprising applying to the skin a polypeptide according to claim 1, a fusion protein according to claim 2 and / or a composition according to claim 7, and optionally applying to the skin other cosmetic and / or make-up products; Preferably, the cosmetic or beauty method is a skin anti-wrinkle, spot lightening and / or whitening method; Preferably, administration is topical or to the skin.
9. Use of the polypeptide according to claim 1, the fusion protein according to claim 2, the nucleic acid according to claim 3, the vector according to claim 4 and / or the host cell according to claim 5 in medicine, cosmetics or beauty products, Preferably, wherein the product is a product for external use, Preferably, the cosmetic or beauty product is a skin anti-wrinkle, oil control, repair and / or soothing product; Preferably, the product is selected from biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D Printing artificial organ biomaterials.
10. Use of the polypeptide according to claim 1, the fusion protein according to claim 2, the nucleic acid according to claim 3, the vector according to claim 4, the host cell according to claim 5, and / or the composition according to claim 7 in preparing a kit for treating or assisting in the treatment of tumors, anti-infection and / or skin wound repair.
11. A method for promoting cell adhesion, comprising the step of contacting cells with the polypeptide according to claim 1 and / or the composition according to claim 7.
Citation Information
Patent Citations
Fibronectin fragment to be used for stem cell production
CN109790536A
Protein and application of protein in wound repair and bacteriostasis
CN111423516A
Recombinant fibronectin with anti-wrinkle repairing function and preparation method and application of recombinant fibronectin
CN111548410A
Lymphocyte production method
CN111655842A
Biosynthetic recombinant human chemical fibronectin and preparation method thereof
CN116589560A
Cited By
Recombinant fibronectin fusion protein and application thereof
CN119331111A
Recombinant fibronectin as well as preparation method, purification method and application thereof
CN119775389A
Recombinant human fibronectin, preparation method and application of recombinant human fibronectin in cosmetics
CN120554537A
Biological agent with bionic ECM structure and application of biological agent in skin anti-aging field
CN121471379A
A biomimetic ECM structure and its application in the field of skin anti-aging
CN121471379B
